Routine screening for hepatitis B
and C has become a must prior to initiation of chronic immunosuppressive
therapy for psoriasis.
“Universal screening for hepatitis B and hepatitis C
infection is not optional in 2013,” he stressed at the Hawaii
Dermatology Seminar sponsored by Global Academy for Medical
Education/Skin Disease Education Foundation.
That said, professional society guidelines are at
odds and in flux on this issue. The American Association for the Study
of Liver Diseases, the European Association for the Study of the Liver,
and the Centers for Disease Control and Prevention all recommend routine
screening for hepatitis B surface antigen and hepatitis B core antibody
prior to initiation of immunosuppressive therapy. The CDC also
recommends universal pretreatment testing for antibody to hepatitis B